Abstract:Neurofibrillary tangles (NFTs), consisting of aggregates of abnormally hyperphosphorylated tau, are indicated in the pathogenesis of several neurodegenerative diseases including Alzheimer's disease (AD). Although hyperphosphorylation of tau is thought to cause aggregation and dissociation of tau from microtubules, the molecular mechanisms underlying the regulation of tau phosphorylation are largely unknown. While the PI3K/Akt pathway has increasingly been shown to regulate multiple cellular events pertinent to AD pathogenesis, including β–amyloid metabolism and tau phosphorylation via GSK–3, potential functions of tumor suppressor PTEN in AD pathogenesis have not been explored. In our study, we explored the molecular mechanisms for regulation of tau phosphorylation by asking the question that if PTEN, a tumor suppressor in PI3K/Akt signaling pathway, can affect tau phosphorylation at Akt and GSK–3 phosphorylation sites and the consequential effects on tau aggregation and binding to microtubules. We examined the effects of PTEN on tau phosphorylation, its microtubule association and formation of aggregates. We cotransfected COS–7 cells with human tau and human wild–type or phosphatase activity null mutant PTEN. We evaluated PTEN's effects on tau phosphorylation by using phospho–tau specific antibodies. To assess PTEN's effects on tau aggregation and binding to microtubules, we performed filter–retardation assay to detect and compare tau aggregates in cultured cells in the presence of wild–type or mutant PTEN. In addition, we fractioned the cotransfected cells to detect and compare the cytosolic, microtubule–bound, membrane–bound and insoluble aggregated tau between cells expressing wild–type and the mutant PTEN. Moreover, we infected rat cortical primary neurons with Sindbis viruses expressing wild–type or the mutant PTEN to monitor neuronal growth. At last, we performed immunohistology to compare phospho–tau and PTEN levels between AD patient and non–AD brains. 1. PTEN affects tau phosphorylation at Akt and GSK–3 phosphorylation sites. 2. PTEN affects tau aggregation and binding to microtubules. 3. PTEN's effects on tau phosphorylation are partially through PIP3/Akt signaling pathway.

Effects of P301L-TAU on post-translational modifications of microtubules in human iPSC-derived cortical neurons and TAU transgenic mice

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Tau Modulates mRNA Transcription, Alternative Polyadenylation Profiles of hnRNPs, Chromatin Remodeling and Spliceosome Complexes

Tau P301L disengages from the proteosome core complex and neurogranin coincident with enhanced neuronal network excitability

The disease-causing tau V337M mutation induces tau hypophosphorylation and perturbs axon morphology pathways

Abnormal tau induces cognitive impairment through two different mechanisms: synaptic dysfunction and neuronal loss

Protein tau phosphorylation in the proline rich region and its implication in the progression of Alzheimer's disease

MAPT Mutations V337M and N297K Alter Organelle Trafficking in Frontotemporal Dementia Patient-Specific Motor Neurons

Knockdown of TTLL1 reduces Aβ-induced TAU pathology in human iPSC-derived cortical neurons

Pathogenic missense MAPT mutations differentially modulate tau aggregation propensity at nucleation and extension steps

A Unique Tau Conformation Generated by an Acetylation-Mimic Substitution Modulates P301S-dependent Tau Pathology and Hyperphosphorylation.

Posttranslational Modifications of Tau - Role in Human Tauopathies and Modeling in Transgenic Animals

Behavioral and neuropathological characterization over the adult lifespan of the human tau knock-in mouse

Disruption of tubulin-alpha4a polyglutamylation prevents aggregation of hyper-phosphorylated tau and microglia activation in mice

Cell-specific MAPT gene expression is preserved in neuronal and glial tau cytopathologies in progressive supranuclear palsy

High-content image-based analysis and proteomic profiling identifies Tau phosphorylation inhibitors in a human iPSC-derived glutamatergic neuronal model of tauopathy

O2-01-05

Differential compartmental processing and phosphorylation of pathogenic human tau and native mouse tau in the line 66 model of frontotemporal dementia

Novel tau filament folds in individuals with MAPT mutations P301L and P301T

P3‐200: TAU‐MEDIATED CELL DEATH MECHANISMS IN MAPT V337M IPSC‐DERIVED HUMAN NEURONS

Hyperphosphorylated Human Tau Accumulates at the Synapse, Localizing on Synaptic Mitochondrial Outer Membranes and Disrupting Respiration in a Mouse Model of Tauopathy